Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn’s disease

Table 1 Patient’s demographic characteristics (n = 62) n (%)

Patient’s demographic characteristics (n = 62)
Female, n (%)	31 (50)
Age at inclusion, mean (min-max)	39 (18-72)
Disease duration (yr), mean (min-max)	9 (0-33)
Location
Terminal ileum	32 (52)
Colonic	15 (24)
Ileocolonic	15 (24)
Associated upper involvement	3 (5)
Phenotype
Inflammatory	39 (63)
Stricturing	14 (22)
Penetrating	9 (15)
Associated structuring + penetrating	4 (7)
Perianal disease	16 (26)
Current smokers	19 (31)
Anti-TNFdrug used
Infliximab	34 (55)
Adalimumab	28 (45)
Prior anti-TNF exposure	16 (26)
Immunomodulators at baseline	53 (86)
Steroids at baseline	13 (21)
Previous CD surgery	9 (15)

TNF: Tumor necrosis factor; CD: Crohn’s disease.